By: Benzinga
January 14, 2013 at 20:17 PM EST
FDA Approves Santarus' UCERIS for Induction of Remission in Patients with Active, Mild to Moderate Ulcerative Colitis
Santarus (NASDAQ: SNTS ) announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS™ (budesonide) extended release tablets for the induction of remission in patients with
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here